Altamira Therapeutics Files December 2024 6-K Report
Ticker: CYTOF · Form: 6-K · Filed: Dec 20, 2024 · CIK: 1601936
Sentiment: neutral
Topics: reporting, foreign-private-issuer
Related Tickers: ALTA
TL;DR
Altamira Therapeutics (ALTA) filed its monthly 6-K report for December 2024.
AI Summary
Altamira Therapeutics Ltd. filed a Form 6-K on December 20, 2024, reporting for the month of December 2024. The company, formerly known as Auris Medical Holding Ltd., is incorporated in Bermuda and its principal executive office is located in Hamilton. This filing is a report of a foreign private issuer.
Why It Matters
This filing provides routine updates for foreign private issuers, informing investors about the company's ongoing reporting status.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational disclosures that would indicate a change in risk.
Key Players & Entities
- Altamira Therapeutics Ltd. (company) — Filer of the report
- Auris Medical Holding Ltd. (company) — Former company name
- December 2024 (date) — Reporting period
- 20241220 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
When was Altamira Therapeutics Ltd. formerly known as Auris Medical Holding Ltd.?
Altamira Therapeutics Ltd. was formerly known as Auris Medical Holding Ltd. on March 18, 2019, and also as Auris Medical Holding AG on March 14, 2019.
Where is Altamira Therapeutics Ltd.'s principal executive office located?
Altamira Therapeutics Ltd.'s principal executive office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda.
Does Altamira Therapeutics Ltd. file annual reports under Form 20-F or Form 40-F?
Altamira Therapeutics Ltd. files annual reports under cover of Form 20-F.
What is the SEC file number for Altamira Therapeutics Ltd.?
The SEC file number for Altamira Therapeutics Ltd. is 001-36582.
Filing Stats: 238 words · 1 min read · ~1 pages · Grade level 14.5 · Accepted 2024-12-20 08:00:15
Filing Documents
- ea0225514-6k_altamira.htm (6-K) — 11KB
- ea022551401ex99-1_altamira.htm (EX-99.1) — 7KB
- 0001213900-24-110771.txt ( ) — 20KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-36582 Altamira Therapeutics Ltd. (Exact name of registrant as specified in its charter) Clarendon House, 2 Church Street Hamilton HM 11, Bermuda (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F INCORPORATION BY REFERENCE This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Numbers 333-249347 , 333-264298 , 333-267584 , 333-272338 , and 333-276427 ) and Form S-8 (Registration Numbers 333-232735 , 333-252141 , and 333-278595 ) of Altamira Therapeutics Ltd. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Altamira Therapeutics Ltd. Date: December 20, 2024 By: /s/ Thomas Meyer Name: Thomas Meyer Title: Chief Executive Officer 2 EXHIBIT INDEX Exhibit Number Description 99.1 Press Release dated December 20, 2024 3